Portola: My Investment Thinking After the Sharp Price Drop (PTLA, Buy, $14.85)Friday, January 10, 2020 · 3:13 pm |
|
Portola: Detailed Spreadsheet Projecting Sales and Earnings Through 4Q, 2021 (PTLA, Buy, $28.00)Friday, November 8, 2019 · 1:24 pm |
|
Portola: Andexxa Looks to be a Blockbuster (PTLA, $30.00, Buy)Thursday, August 8, 2019 · 12:38 pm |
|
Portola: Andexxa Sales in 1Q, 2019 Were Encouraging and Yet the Stock HasTraded Down (PTLA, Buy, $30.16)Wednesday, May 8, 2019 · 12:40 pm |
|
Portola: Detailed Update on Exciting 2019 Outlook (PTLA, Buy, $33.35)Wednesday, March 13, 2019 · 2:38 pm |
|
Portola: NEJM Report on Positive Results in ANNEXA-4 Study is a Significant Positive (PTLA, Buy, $28.89)Monday, February 11, 2019 · 11:06 am |
|
Portola: Tidbits from Presentation at JP Morgan Healthcare Conference (PTLA, Buy, $21.96)Tuesday, January 8, 2019 · 12:54 pm |
|
Portola: Approval of Gen 2 Manufacturing Process for AndexXa is a Significant Positive (PTLA, Buy, $18.75)Wednesday, January 2, 2019 · 10:33 am |
|
Portola Pharmaceuticals: 2019 Is All About the Sales Trajectory of AndexXa (PTLA, $15.46, Buy)Sunday, December 23, 2018 · 9:04 am |
|
Portola: Reiteration of Buy Recommendation (PTLA, Buy, S27.46)Monday, September 10, 2018 · 12:22 pm |
|
Portola: Update and Reiteration of Buy Recommendation (PTLA, Buy, $39.31)Thursday, July 12, 2018 · 9:13 am |
|
Portola: Approval of AndexXa is a Major Positive (PTLA, Buy, $41.19)Friday, May 4, 2018 · 12:18 pm |
|
Portola: Why I Think that AndexXa is Likely to be Approved (PTLA, Buy, $36.44)Thursday, March 15, 2018 · 9:57 am |
|
Portola: Uncertainty on AndexXa Approval Leads to 30% Decline in Stock Price (PTLA, Buy, $31.16)Thursday, March 1, 2018 · 11:54 am |
|
Portola Announces a Delay in PDUFA Date for AndexXa (PTLA, Buy, $54.86)Monday, December 25, 2017 · 10:28 am |
|
Portola: US Launch of Bevyexxa Is Scheduled for Early January 2018 (PTLA, Buy, $50.03)Tuesday, December 19, 2017 · 1:07 pm |
|
Portola: Management Guides to a Highly Probable US Launch of Bevyexxa in the December to February Timeframe (PTLA, Buy, $50.52)Tuesday, November 7, 2017 · 11:43 am |
|
Portola: Reiterating Buy and Refuting Recent Negative Blog by Adam F-stein (PTLA, Buy, $54.12)Sunday, September 24, 2017 · 9:30 am |
|
Portola: September 4 Conference Call Provides Update on Potential Launch Date for Bevyxxa and Announces Price (PTLA, Buy, $57.29)Wednesday, September 6, 2017 · 10:18 am |
|
Portola Pharmaceuticals: AndexXa BLA Resubmitted; Reiterating Buy (PTLA, $61.41, Buy)Tuesday, August 8, 2017 · 12:45 pm |
|
Portola Pharmaceuticals: Betrixaban Approval Triggers Big Stock Move-Now What Do We Do? (PTLA, Buy, $55.42)Thursday, June 29, 2017 · 9:09 am |
|
Portola: Reiterating Buy Prior to June 24th PDUFA Date for Betrixaban (PTLA, Buy, $39.35)Thursday, June 22, 2017 · 11:08 am |
|
Portola Pharmaceuticals: Initiating Coverage with a Buy (PTLA, $40.05)Thursday, May 4, 2017 · 10:47 am |
|
|
There are 23 reports on file. |
